Skip to main content

Clinical Trials Using Capecitabine

Review the clinical trials studying capecitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 86

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Status: Active
Location: 1034 locations
Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Status: Active
Location: 1013 locations
Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Status: Active
Location: 431 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 324 locations
Testing Chemotherapy versus Chemotherapy plus Radiotherapy Prior to Limited Surgery for Early Rectal Cancer
Status: Active
Location: 106 locations
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Status: Active
Location: 54 locations
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Status: Active
Location: 47 locations
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Status: Active
Location: 31 locations
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Status: Active
Location: 28 locations
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Status: Active
Location: 25 locations
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Status: Active
Location: 17 locations
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Status: Active
Location: 15 locations
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Status: Active
Location: 14 locations
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Status: Active
Location: 18 locations
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Status: Active
Location: 12 locations
Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician's Choice for the Treatment of Patients with AR-Positive Metastatic Triple-Negative or ER-Low Breast Cancer
Status: Active
Location: 12 locations
Dostarlimab before Chemoradiotherapy and Surgery for the Treatment of Locally Advanced Mismatch Repair Deficiency or Microsatellite Instability Solid Tumors and Stage I-II Endometrial Cancer
Status: Active
Location: 11 locations
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Status: Active
Location: 11 locations
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Status: Active
Location: 10 locations
Pembrolizumab with Trastuzumab and Chemotherapy for the Treatment Resectable HER2-Positive Gastric, Esophageal, and Gastroesophageal Junction Cancer
Status: Active
Location: 10 locations
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Status: Active
Location: 10 locations
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Status: Active
Location: 15 locations
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Status: Active
Location: 8 locations
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Status: Active
Location: 7 locations
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Status: Active
Location: 7 locations